Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BHV-8000 in adults with early Parkinson's disease
NL-OMON59018Phase 3Not yet recruiting
- Sponsor
- Biohaven Ltd.
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of BHV-8000 in Parkinson's disease (PD) (3 arms), sponsored by Biohaven Ltd. Primary endpoint: Time to first qualifying worsening event on MDS-UPDRS Part II. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
BHV-8000
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NL-OMON59018.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59018.